ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
Dow Jones
44.544,66
-0,75%
Euro vs US Dollar
1,0366
0,04%
Bitcoin
98.995,14
-1,67%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Tyra Biosciences Inc (TYRA)

  7. Tyra Biosciences Inc (TYRA) News

TYRA

Tyra Biosciences (TYRA)

Tyra Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TYRA
DatumZeitQuelleÜberschriftSymbolFirma
29/01/202522h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
29/01/202522h05PR Newswire (US)Tyra Biosciences Announces Appointment of Adele Gulfo to Board of DirectorsNASDAQ:TYRATyra Biosciences Inc
23/01/202500h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
22/01/202514h00PR Newswire (US)Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers SymposiumNASDAQ:TYRATyra Biosciences Inc
10/01/202514h00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)NASDAQ:TYRATyra Biosciences Inc
09/12/202423h42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
07/12/202403h30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
07/12/202403h30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
05/12/202422h21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
03/12/202401h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
20/11/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
20/11/202403h31Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
14/11/202423h52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
13/11/202422h05PR Newswire (US)Tyra Biosciences to Present at Upcoming Investor ConferencesNASDAQ:TYRATyra Biosciences Inc
07/11/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
07/11/202422h05PR Newswire (US)Tyra Biosciences Reports Third Quarter 2024 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
30/10/202421h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
28/10/202422h15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
28/10/202412h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
28/10/202412h00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)NASDAQ:TYRATyra Biosciences Inc
25/10/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
25/10/202400h21PR Newswire (US)Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)NASDAQ:TYRATyra Biosciences Inc
23/10/202422h05PR Newswire (US)Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ETNASDAQ:TYRATyra Biosciences Inc
23/10/202403h15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
23/10/202402h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
23/10/202402h47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
18/10/202422h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
11/10/202414h00PR Newswire (US)Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)NASDAQ:TYRATyra Biosciences Inc
18/09/202422h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
18/09/202421h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:TYRA

Kürzlich von Ihnen besucht

FX
EURJPY
Euro vs Yen
COIN
ADAUSD
Cardano
COIN
XRPUSD
Ripple
NYSE
NKE
Nike
DBI
MDAX
MDAX
USOTC
ADDYY
Adidas (QX)
NYSE
MCD
McDonalds
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
NASDAQ
AMZN
Amazon.com
COIN
DOGEUSD
Dogecoin
USOTC
BNPQY
BNP Paribas (QX)
TG
BAYN
Bayer
FX
EURUSD
Euro vs US Dollar
TG
NOV
Novo Nordisk
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten